November 2020 at a glance: focus on comorbidities and medical treatment
暂无分享,去创建一个
[1] F. Iellamo,et al. Effects of hyperkalaemia and non‐adherence to renin–angiotensin–aldosterone system inhibitor therapy in patients with heart failure in Italy: a propensity‐matched study , 2020, European journal of heart failure.
[2] P. Ponikowski,et al. Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC‐HF baseline characteristics and comparison with contemporary clinical trials , 2020, European journal of heart failure.
[3] S. Solomon,et al. Sex‐based differences in biomarkers, health status, and reverse cardiac remodelling in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan , 2020, European journal of heart failure.
[4] Akshay S. Desai,et al. Serum uric acid, influence of sacubitril–valsartan, and cardiovascular outcomes in heart failure with preserved ejection fraction: PARAGON‐HF , 2020, European journal of heart failure.
[5] Akshay S. Desai,et al. Serum potassium in the PARADIGM‐HF trial , 2020, European journal of heart failure.
[6] J. McMurray,et al. Cost‐effectiveness of dapagliflozin as a treatment for heart failure with reduced ejection fraction: a multinational health‐economic analysis of DAPA‐HF , 2020, European journal of heart failure.
[7] R. Holman,et al. Association between glycated haemoglobin levels and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease: a secondary analysis of the TECOS randomized clinical trial , 2020, European journal of heart failure.
[8] T. Kitai,et al. Prevalence and prognostic impact of the coexistence of multiple frailty domains in elderly patients with heart failure: the FRAGILE‐HF cohort study , 2020, European journal of heart failure.
[9] Akshay S. Desai,et al. The prevalence and importance of frailty in heart failure with reduced ejection fraction – an analysis of PARADIGM‐HF and ATMOSPHERE , 2020, European journal of heart failure.
[10] E. Giannitsis,et al. Cardiac iron concentration in relation to systemic iron status and disease severity in non‐ischaemic heart failure with reduced ejection fraction , 2020, European journal of heart failure.
[11] R. Doughty,et al. Circulating levels and prognostic value of soluble ST2 in heart failure are less influenced by age than N‐terminal pro‐B‐type natriuretic peptide and high‐sensitivity troponin T , 2020, European journal of heart failure.
[12] P. Ponikowski,et al. Heart Failure Association of the European Society of Cardiology position paper on frailty in patients with heart failure , 2019, European journal of heart failure.
[13] S. Solomon,et al. Insulin treatment and clinical outcomes in patients with diabetes and heart failure with preserved ejection fraction , 2019, European journal of heart failure.
[14] G. Filippatos,et al. Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations , 2019, European journal of heart failure.
[15] A. Banerjee,et al. Risk factors for incident heart failure in age‐ and sex‐specific strata: a population‐based cohort using linked electronic health records , 2019, European journal of heart failure.
[16] J. Regensteiner,et al. Impact of diabetes and sex in heart failure with reduced ejection fraction patients from the ASIAN‐HF registry , 2018, European journal of heart failure.
[17] Akshay S. Desai,et al. The frailty syndrome and outcomes in the TOPCAT trial , 2018, European journal of heart failure.
[18] D. Pennell,et al. Sex‐ and age‐based differences in the natural history and outcome of dilated cardiomyopathy , 2018, European journal of heart failure.
[19] L. Lund,et al. Incidence, predictors and clinical management of hyperkalaemia in new users of mineralocorticoid receptor antagonists , 2018, European journal of heart failure.
[20] E. Steyerberg,et al. Prognostic value of psychosocial factors for first and recurrent hospitalizations and mortality in heart failure patients: insights from the OPERA‐HF study , 2018, European journal of heart failure.
[21] B. Giepmans,et al. Iron deficiency impairs contractility of human cardiomyocytes through decreased mitochondrial function , 2018, European journal of heart failure.
[22] P. Ponikowski,et al. Potassium and the use of renin–angiotensin–aldosterone system inhibitors in heart failure with reduced ejection fraction: data from BIOSTAT‐CHF , 2018, European journal of heart failure.
[23] K. Dickstein,et al. Treatment with insulin is associated with worse outcome in patients with chronic heart failure and diabetes , 2017, European journal of heart failure.
[24] S. Silver,et al. Heart Failure , 1937, The New England journal of medicine.